Abstract:GBM (glioblastoma) is the most common and aggressive primary brain tumor in adults. Immunotherapy is an emerging and promising treatment modality for GBM. Unfortunately, most immunotherapy trials have provided only modest benefit to GBM patients thus far. A significant barrier that limits efficacy of immunotherapy in GBM is the paucity of tumor infiltrating lymphocytes and abundance of immune suppressive myeloid cells. A critical step in enhancing the efficacy of immunotherapy for GBM requires approaches that enhance T cell infiltration and reprogram the myeloid cells to a more pro-inflammatory state. S100A4 is a major regulator of stemness, epithelial-mesenchymal transition, and immunosuppression in glioma stem cells and a critical regulator of immune suppressive myeloid and T cell phenotypes in GBM. Targeting S100A4 in either glioma cells or stromal cells is sufficient to reprogram the tumor immune landscape and extend survival of glioma bearing mice, indicating that S100A4 is a promising immunotherapy target. Since S100A4 has both intracellular and extracellular function as well as cytokine-like function, we developed a S100A4 blocking antibody. While the anti-S100A4 antibody blocks breast cancer metastasis efficiently, it did not cross the BBB. Hence, we generated a bispecific S100A4-TfR antibody (BsA) that allows robust BBB penetration. Using ELISA, confocal immunofluorescent microscopy, and multiplexed flow cytometry, our preliminary results suggest that systemic administration of the S100A4-TfR BsA results in accumulation of BsA in the brain and glioma tissue, increased T cell infiltration and immune remodeling. Furthermore, the BsA is taken up by glioma cells and accumulates intracellularly, which is correlated with decreased nuclear SOX2 expression. These results suggest that S100A4-TfR BsA is a promising agent to treat GBM to reprogram the GBM immune landscape and reduce stemness. We are currently performing single cell RNA-sequencing to elucidate molecular and cellular changes induced by the bispecific antibody treatment in different cell types and performing long term survival analyses to evaluate its therapeutic potential. Citation Format: Thomas Wong, Jia-Shiun Leu, Xuejun Fan, Reece Kang, Nourhan Abdelfattah, Fransisca Leonard, Ningyan Zhang, Kyuson Yun. A novel bispecific antibody to reprogram the immune suppressive GBM TME [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2711.

A Cholesterol Metabolic Regulated Hydrogen-Bonded Organic Framework (Hof)-Based Biotuner for Antibody Non-Dependent Immunotherapy Tailored for Glioblastoma.

Bimetallic Peroxide-Based Nanotherapeutics for Immunometabolic Intervention and Induction of Immunogenic Cell Death to Augment Cancer Immunotherapy

Simultaneous Modulation of Hypoxia And Metabolism in Glioblastoma for Enhanced Radio‐Immunotherapy

Targeted Regulation of Blood-Brain Barrier for Enhanced Therapeutic Efficiency of Hypoxia-Modifier Nanoparticles and Immune Checkpoint Blockade Antibodies for Glioblastoma

Oncolytic viruses engineered to enforce cholesterol efflux restore tumor-associated macrophage phagocytosis and anti-tumor immunity in glioblastoma

Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma

Metal-organic framework nanoagent induces cuproptosis for effective immunotherapy of malignant glioblastoma

High Density Lipoprotein-Mimicking Nanodiscs for Chemo-Immunotherapy against Glioblastoma Multiforme.

Metabolism/Immunity Dual‐Regulation Thermogels Potentiating Immunotherapy of Glioblastoma Through Lactate‐Excretion Inhibition and PD‐1/PD‐L1 Blockade

Effective glioblastoma immune sonodynamic treatment mediated by macrophage cell membrane cloaked biomimetic nanomedicines

A multifunctional targeted nano-delivery system with radiosensitization and immune activation in glioblastoma

Donor Substitution Engineering of Hemicyanine Nanoparticles to Reprogram the Tumor Microenvironment and Enhance Fn14‐Targeted BiTE for Glioblastoma Photoimmunotherapy

Cholesterol metabolism and its implication in glioblastoma therapy

Biomimetic nanoparticles directly remodel immunosuppressive microenvironment for boosting glioblastoma immunotherapy

A biomimetic targeted nanosystem delivering synergistic inhibitors for glioblastoma immune microenvironment reprogramming and treatment

Allomelanin-based biomimetic nanotherapeutics for orthotopic glioblastoma targeted photothermal immunotherapy

Recruiting T Cells towards Brain for Enhanced Glioblastoma Immunotherapeutic Efficacy by Co‐delivery of Cytokines and Immune Checkpoint Antibodies with Macrophage Membrane‐Camouflaged Nano Vesicles

Abstract 2711: A novel bispecific antibody to reprogram the immune suppressive GBM TME

Modulation of blood-tumor barrier transcriptional programs improves intra-tumoral drug delivery and potentiates chemotherapy in GBM

Immu-62. Invigorating Effector Immune Cells With Highly Selective Il-2R Agonists And Potential Synergy With Tumor Targeting Therapeutics For Treatment Of Glioblastomas

In Situ Attached Photothermal Immunomodulation-Enhanced Nanozyme for the Inhibition of Postoperative Malignant Glioma Recurrence.